Developer docs
API playgroundTry for free, no card

Search company profiles

Motif Neurotech

Full company profile

uuid0000l38

Namestring
Motif Neurotech
Legal namestring
Motif Neurotech, Inc.
Websiteurl
motifneuro.tech
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Motif Neurotech is a clinical-stage medical device company developing minimally invasive, battery-free bioelectronic implants for the monitoring and treatment of severe mental illness, with an initial focus on treatment-resistant depression (TRD) in adults who have failed two or more antidepressant medications. The company's lead product is the DOT / DOT XCS System, a pea- to blueberry-sized implant placed in the skull bone above the dura that never contacts brain tissue and is implanted in a roughly 20-30 minute outpatient procedure. DOT wirelessly stimulates the Central Executive Network (CEN) using patent-pending magnetoelectric wireless power transfer technology originally developed at Rice University's Robinson Lab, and is paired with an external wearable hat that delivers prescribed stimulation sessions of about 30 minutes at home. A recently announced multi-year commercial supply agreement with MintNeuro adds specialized miniaturized neural-interface chips to the platform across pre-clinical, early clinical, and pivotal-trial phases.

Motif received FDA Breakthrough Device Designation for its XCS implant and, in April 2026, became the fastest implantable BCI company to advance from founding to FDA Investigational Device Exemption (IDE) approval, achieved in just four years. The company is currently running the RESONATE Early Feasibility Study across up to eight U.S. medical institutions including Baylor College of Medicine, Massachusetts General Brigham, and Emory Healthcare, enrolling approximately 10 participants and tracking safety over 12 months. It holds granted patents in the United States, Europe, and Japan covering the DOT device. Leadership combines academic neuroscience (CEO Jacob Robinson, PhD, with 60+ peer-reviewed publications and $40M+ federal funding from Rice) with industry neuromodulation depth (CTO Steve Goetz, Bakken Fellow with 160+ patents from 26 years at Medtronic) and practicing neurosurgery founders (Sameer Sheth, Sunil Sheth).

The company is pre-revenue and sells no commercial product today; its only cash inflows are equity financings and non-dilutive grants. As of December 2025 Motif had raised over $30M in cumulative venture capital, anchored by an $18.75M Series A closed in January 2024 with a syndicate led by Arboretum Ventures and including Satori Capital, Capital Factory, Divergent Capital, Dolby Family Ventures, Empath Ventures, KdT Ventures, PsyMed Ventures, re.Mind Capital, and TMC Innovation. Non-dilutive capital includes a £5.8M UK ARIA grant (January 2025) and selection into the ARPA-H EVIDENT federal initiative (April 2026), a program that may allocate up to $139.4M to mental health therapies. Future commercialization is expected to flow through leading U.S. academic medical centers and specialty neurology and psychiatry practices via a direct sales motion, with device pricing to be set after FDA marketing authorization.

Short descriptiontext

Motif Neurotech is a clinical-stage medical device company developing the DOT implant, a minimally invasive, battery-free brain stimulator that uses magnetoelectric wireless power to treat treatment-resistant depression in patients who have failed multiple antidepressants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic brain-computer interface, implantable neuromodulation devices, treatment-resistant depression therapy, wireless bioelectronic implants, magnetoelectric neural stimulation
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Neuromodulation Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue (clinical-stage)
TypeHardware Sales
Description

Motif Neurotech is pre-revenue: the company is conducting its first-in-human RESONATE Early Feasibility Study (IDE approved April 27, 2026) for the DOT device in treatment-resistant depression. Future commercialization will rely on selling or implanting the DOT/DOT XCS System into healthcare systems.

finance.yahoo.com
2Non-dilutive Grant Funding
TypeSubscription Recurring
Description

Receives non-dilutive funding from government grant programs (UK ARIA awards of $5.8M; £4.7M UK ARIA-funded Brain Mesh project; ARPA-H EVIDENT initiative participation up to $139.4M in federal funding). These are funding sources, not commercial revenue.

siliconsemiconductor.net
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Not publicly disclosed (pre-commercial clinical-stage product)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing for the DOT / DOT XCS System is not listed. Device pricing will depend on outcome of RESONATE Early Feasibility Study and subsequent FDA approval pathway for treatment-resistant depression.

motifneuro.tech
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DOT
Description

DOT (Digitally programmable Over-brain Therapeutic) — Motif's miniature, wirelessly powered, skull-implanted brain-computer interface designed to stimulate the Central Executive Network for treatment-resistant depression. Described as blueberry- or pea-sized.

motifneuro.tech
+1 more record
Core offering1 text field

Motif Neurotech develops a minimally invasive, wirelessly powered implantable brain stimulator called DOT (Digitally programmable Over-brain Therapeutic), also referenced as the DOT XCS System. The pea-sized, battery-free device is implanted in the skull bone above the dura in a ~20–30 minute outpatient procedure and pairs with a wearable hat controller to deliver targeted stimulation of the Central Executive Network (CEN) for the treatment of treatment-resistant depression. The company is clinical-stage, having received FDA Investigational Device Exemption (IDE) approval in April 2026 for its RESONATE Early Feasibility Study.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • FDA IDE approval achieved in just 4 years from founding (fastest implantable BCI company to reach IDE with a novel device)
+4 more records
Product overview1 text field

Motif Neurotech offers a single integrated therapeutic brain-computer interface (BCI) platform anchored by its DOT (Digitally programmable Over-brain Therapeutic) implantable brain stimulator — also referenced as the DOT XCS System — which is paired with a wearable wireless hat controller that delivers at-home outpatient treatment for treatment-resistant depression. The DOT implant and its companion hat transmitter together form the core product architecture, while the Patient Registry serves as the company's clinical-trial engagement service, capturing interest from patients, caregivers, and providers for upcoming RESONATE Early Feasibility Study enrollment.

Product and service3 records
1DOT (Digitally programmable Over-brain Therapeutic) / DOT XCS System
CategoryImplantable Neuromodulation Device
Description

Cosmetically invisible, blueberry- to pea-sized, battery-free implantable brain stimulator placed in the skull bone that wirelessly stimulates the Central Executive Network via magnetoelectric power transfer to treat treatment-resistant depression from home. Implanted in a ~20–30 minute outpatient procedure that does not expose or contact the brain.

2Wireless Wearable Hat Controller (paired transmitter)
CategoryCompanion External Controller / Accessory
Description

A wearable cap-style transmitter that pairs with the DOT implant to wirelessly deliver power and prescribed stimulation sessions, enabling at-home treatment for treatment-resistant depression without repeated clinic visits.

3Patient Registry
CategoryPatient Engagement / Clinical Research Service
Description

Web-based registry that invites individuals with treatment-resistant depression, caregivers, and providers to register interest in upcoming Motif Neurotech clinical trial opportunities and related research.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Strategic partnership combining MintNeuro's miniaturised neural interface chip technology with Motif's clinical-stage therapeutic BCI implant platform for mental health conditions. Includes a multi-year commercial supply agreement spanning pre-clinical, early clinical, and pivotal trial phases. Builds on over a year of joint development, with Motif's sensing chip already integrated into devices used in pre-clinical work. Motif has established a U.K. subsidiary to collaborate with MintNeuro on software and data science tied to the ARIA-funded Brain Mesh project.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-27
Description

Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-27
Description

Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-27
Description

Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Motif Neurotech joined the ARPA-H EVIDENT initiative, which will collectively fund up to $139.4M to develop new effective therapies for behavioral health conditions including depression, anxiety, addiction, and PTSD. The initiative allocates at least $50M to match state government investments in psychedelic research and aims to generate FDA-ready clinical endpoints for rapid-acting therapies such as neuromodulation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-20
Description

Motif won UK government ARIA grants totaling $5.8M to develop its therapeutic brain-computer interface (announced January 20, 2025), aligned with the broader £4.7M Brain Mesh project. Provides non-dilutive funding and integration into ARIA's Precision Neurotechnologies programme.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Rice University is the source of Motif's foundational magnetoelectric wireless power technology, developed over more than a decade by CEO Jacob Robinson's research group. Rice University News (April 28, 2026) explicitly covered 'Brain-computer interface based on Rice research wins FDA approval for first clinical trial'. Founders/advisors Kaiyuan Yang (Associate Professor of ECE, Rice) and Jacob Robinson retain Rice professorships while leading Motif.

Strategic tierCoreTypeOthers
Description

Motif's brand-new lab and manufacturing home is located at Texas Medical Center - Innovation (TMCi), a start-up incubation hub in Houston providing access to cutting-edge resources and industry-leading mentorship.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Utah-based implantable brain-computer interface company developing neural recording/stimulation platforms for paralysis and other indications. Directly comparable as a peer implantable BCI company; COO Nick Halper previously led growth strategy and regulatory work at Blackrock before joining Motif.

TypeDirect peer
Description

Elon Musk-founded implantable BCI company developing high-bandwidth cortical interfaces for paralysis and eventually other applications. Directly comparable as a peer implantable BCI; competes for the same press coverage, talent, and clinical site attention as Motif in the BCI race.

TypeDirect peer
Description

Stentrobot-derived endovascular BCI company targeting paralysis patients via a less-invasive, catheter-delivered electrode. Directly comparable as a peer BCI for clinical applications and as a competitor for patient/clinical-site mindshare in the implantable neurotech category.

TypeDirect peer
Description

Neuralink co-founder-founded BCI company developing a thin-film cortical electrode array for high-resolution brain recording. Directly comparable as a peer implantable BCI startup competing for talent, capital, and clinical milestones in the cortical-interface space.

TypeDirect peer
Description

Austin-based implantable BCI company building high-data-rate neural recording interfaces for medical and communication applications. Directly comparable as a peer implantable BCI startup; competes in the same clinical-stage BCI cohort as Motif.

TypeBroad incumbent
Description

Global medical device leader with deep franchises in deep brain stimulation (Activa), spinal cord stimulation, and other neuromodulation therapies. Broad incumbent in the neuromodulation category; CTO Steve Goetz's 26-year Medtronic tenure and Bakken Fellowship make it the most directly relevant incumbent for talent/technology benchmarking, even though Medtronic's DBS targets movement disorders rather than TRD.

TypeBroad incumbent
Description

Major neuromodulation player with FDA-approved dorsal root ganglion and spinal cord stimulation systems (Proclaim, Eterna) and a deep DBS legacy via the legacy St. Jude portfolio. Broad incumbent in implantable neuromodulation; directly comparable on Class III implant manufacturing, regulatory, and commercial scale.

TypeBroad incumbent
Description

Large-cap medical device incumbent with spinal cord stimulation, deep brain stimulation, and cardiac rhythm management franchises. Broad incumbent in implantable neuromodulation; Director of Manufacturing Jake Wiederin spent more than a decade at Boston Scientific supporting cardiac rhythm and neuromodulation portfolios.

TypeBroad incumbent
Description

Clinical-stage neuromodulation company developing closed-loop spinal cord stimulation for chronic pain with Evoke/ECAP-controlled devices. Comparable as a peer implantable neuromodulation company with a sensing-enabled platform; multiple Motif engineers and staff previously worked at Saluda, making it a near-direct talent/technology comparator.

TypeEmerging player
Description

Commercial-stage company commercializing deep transcranial magnetic stimulation (Deep TMS) systems, including an FDA-cleared protocol for treatment-resistant depression. Comparable as a peer targeting TRD with a non-invasive neuromodulation modality that competes for the same patient population and clinical sites as Motif's eventual DOT offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Motif Neurotech

Implantable Neuromodulation Devicesmotifneuro.tech

Motif Neurotech is a clinical-stage medical device company developing the DOT implant, a minimally invasive, battery-free brain stimulator that uses magnetoelectric wireless power to treat treatment-resistant depression in patients who have failed multiple antidepressants.

What Motif Neurotech does

Motif Neurotech is a clinical-stage medical device company developing minimally invasive, battery-free bioelectronic implants for the monitoring and treatment of severe mental illness, with an initial focus on treatment-resistant depression (TRD) in adults who have failed two or more antidepressant medications. The company's lead product is the DOT / DOT XCS System, a pea- to blueberry-sized implant placed in the skull bone above the dura that never contacts brain tissue and is implanted in a roughly 20-30 minute outpatient procedure. DOT wirelessly stimulates the Central Executive Network (CEN) using patent-pending magnetoelectric wireless power transfer technology originally developed at Rice University's Robinson Lab, and is paired with an external wearable hat that delivers prescribed stimulation sessions of about 30 minutes at home. A recently announced multi-year commercial supply agreement with MintNeuro adds specialized miniaturized neural-interface chips to the platform across pre-clinical, early clinical, and pivotal-trial phases.

Motif received FDA Breakthrough Device Designation for its XCS implant and, in April 2026, became the fastest implantable BCI company to advance from founding to FDA Investigational Device Exemption (IDE) approval, achieved in just four years. The company is currently running the RESONATE Early Feasibility Study across up to eight U.S. medical institutions including Baylor College of Medicine, Massachusetts General Brigham, and Emory Healthcare, enrolling approximately 10 participants and tracking safety over 12 months. It holds granted patents in the United States, Europe, and Japan covering the DOT device. Leadership combines academic neuroscience (CEO Jacob Robinson, PhD, with 60+ peer-reviewed publications and $40M+ federal funding from Rice) with industry neuromodulation depth (CTO Steve Goetz, Bakken Fellow with 160+ patents from 26 years at Medtronic) and practicing neurosurgery founders (Sameer Sheth, Sunil Sheth).

The company is pre-revenue and sells no commercial product today; its only cash inflows are equity financings and non-dilutive grants. As of December 2025 Motif had raised over $30M in cumulative venture capital, anchored by an $18.75M Series A closed in January 2024 with a syndicate led by Arboretum Ventures and including Satori Capital, Capital Factory, Divergent Capital, Dolby Family Ventures, Empath Ventures, KdT Ventures, PsyMed Ventures, re.Mind Capital, and TMC Innovation. Non-dilutive capital includes a £5.8M UK ARIA grant (January 2025) and selection into the ARPA-H EVIDENT federal initiative (April 2026), a program that may allocate up to $139.4M to mental health therapies. Future commercialization is expected to flow through leading U.S. academic medical centers and specialty neurology and psychiatry practices via a direct sales motion, with device pricing to be set after FDA marketing authorization.

Motif Neurotech firmographics

Firmographics
Name
Motif Neurotech
Legal name
Motif Neurotech, Inc.
Website
https://motifneuro.tech
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Motif Neurotech is a clinical-stage medical device company developing the DOT implant, a minimally invasive, battery-free brain stimulator that uses magnetoelectric wireless power to treat treatment-resistant depression in patients who have failed multiple antidepressants.
Ownership category
akta.pro rank

Motif Neurotech industry classification

Industry
Product category
Implantable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Therapeutic brain-computer interface
  • Implantable neuromodulation devices
  • Treatment-resistant depression therapy
  • Wireless bioelectronic implants
  • Magnetoelectric neural stimulation

Where Motif Neurotech is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Motif Neurotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue (clinical-stage): Motif Neurotech is pre-revenue: the company is conducting its first-in-human RESONATE Early Feasibility Study (IDE approved April 27, 2026) for the DOT device in treatment-resistant depression. Future commercialization will rely on selling or implanting the DOT/DOT XCS System into healthcare systems.
  2. Non-dilutive Grant Funding: Receives non-dilutive funding from government grant programs (UK ARIA awards of $5.8M; £4.7M UK ARIA-funded Brain Mesh project; ARPA-H EVIDENT initiative participation up to $139.4M in federal funding). These are funding sources, not commercial revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNot publicly disclosed (pre-commercial clinical-stage product)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Motif Neurotech product offering

Product offering

Core offering

Motif Neurotech develops a minimally invasive, wirelessly powered implantable brain stimulator called DOT (Digitally programmable Over-brain Therapeutic), also referenced as the DOT XCS System. The pea-sized, battery-free device is implanted in the skull bone above the dura in a ~20–30 minute outpatient procedure and pairs with a wearable hat controller to deliver targeted stimulation of the Central Executive Network (CEN) for the treatment of treatment-resistant depression. The company is clinical-stage, having received FDA Investigational Device Exemption (IDE) approval in April 2026 for its RESONATE Early Feasibility Study.

Product overview

Motif Neurotech offers a single integrated therapeutic brain-computer interface (BCI) platform anchored by its DOT (Digitally programmable Over-brain Therapeutic) implantable brain stimulator — also referenced as the DOT XCS System — which is paired with a wearable wireless hat controller that delivers at-home outpatient treatment for treatment-resistant depression. The DOT implant and its companion hat transmitter together form the core product architecture, while the Patient Registry serves as the company's clinical-trial engagement service, capturing interest from patients, caregivers, and providers for upcoming RESONATE Early Feasibility Study enrollment.

Differentiator

Problem solved

Functional benefit

Brands

  • DOT: DOT (Digitally programmable Over-brain Therapeutic) — Motif's miniature, wirelessly powered, skull-implanted brain-computer interface designed to stimulate the Central Executive Network for treatment-resistant depression. Described as blueberry- or pea-sized.
  • DOT XCS System

Products and services

  • DOT (Digitally programmable Over-brain Therapeutic) / DOT XCS System Cosmetically invisible, blueberry- to pea-sized, battery-free implantable brain stimulator placed in the skull bone that wirelessly stimulates the Central Executive Network via magnetoelectric power transfer to treat treatment-resistant depression from home. Implanted in a ~20–30 minute outpatient procedure that does not expose or contact the brain.
  • Wireless Wearable Hat Controller (paired transmitter) A wearable cap-style transmitter that pairs with the DOT implant to wirelessly deliver power and prescribed stimulation sessions, enabling at-home treatment for treatment-resistant depression without repeated clinic visits.
  • Patient Registry Web-based registry that invites individuals with treatment-resistant depression, caregivers, and providers to register interest in upcoming Motif Neurotech clinical trial opportunities and related research.

Quantifiable outcome

  • FDA IDE approval achieved in just 4 years from founding (fastest implantable BCI company to reach IDE with a novel device)
  • +4 more outcomes

Companies that use Motif Neurotech

Customer profile

Ideal customer profiles3 records

Motif Neurotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Motif Neurotech partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • MintNeuroflagshipStrategic or Co-development Partner · 30 April 2026Strategic partnership combining MintNeuro's miniaturised neural interface chip technology with Motif's clinical-stage therapeutic BCI implant platform for mental health conditions. Includes a multi-year commercial supply agreement spanning pre-clinical, early clinical, and pivotal trial phases. Builds on over a year of joint development, with Motif's sensing chip already integrated into devices used in pre-clinical work. Motif has established a U.K. subsidiary to collaborate with MintNeuro on software and data science tied to the ARIA-funded Brain Mesh project.
  • Baylor College of MedicinecoreImplementation/ SI/ Consulting Partner · 27 April 2026Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
  • Massachusetts General BrighamcoreImplementation/ SI/ Consulting Partner · 27 April 2026Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
  • Emory HealthcarecoreImplementation/ SI/ Consulting Partner · 27 April 2026Clinical trial site for the RESONATE Early Feasibility Study of Motif's DOT device in treatment-resistant depression. Listed among up to eight leading U.S. medical institutions hosting the trial.
  • ARPA-H (U.S. HHS) — EVIDENT initiativeflagshipStrategic or Co-development Partner · 21 April 2026Motif Neurotech joined the ARPA-H EVIDENT initiative, which will collectively fund up to $139.4M to develop new effective therapies for behavioral health conditions including depression, anxiety, addiction, and PTSD. The initiative allocates at least $50M to match state government investments in psychedelic research and aims to generate FDA-ready clinical endpoints for rapid-acting therapies such as neuromodulation.
  • UK Government ARIA (Advanced Research and Invention Agency)flagshipStrategic or Co-development Partner · 20 January 2025Motif won UK government ARIA grants totaling $5.8M to develop its therapeutic brain-computer interface (announced January 20, 2025), aligned with the broader £4.7M Brain Mesh project. Provides non-dilutive funding and integration into ARIA's Precision Neurotechnologies programme.
  • Rice University (Robinson Lab)flagshipStrategic or Co-development Partner · 1 January 2022Rice University is the source of Motif's foundational magnetoelectric wireless power technology, developed over more than a decade by CEO Jacob Robinson's research group. Rice University News (April 28, 2026) explicitly covered 'Brain-computer interface based on Rice research wins FDA approval for first clinical trial'. Founders/advisors Kaiyuan Yang (Associate Professor of ECE, Rice) and Jacob Robinson retain Rice professorships while leading Motif.
  • Texas Medical Center - Innovation (TMCi)coreOthersMotif's brand-new lab and manufacturing home is located at Texas Medical Center - Innovation (TMCi), a start-up incubation hub in Houston providing access to cutting-edge resources and industry-leading mentorship.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Motif Neurotech competitors and assessment

Company assessment

Direct peers

  • Blackrock Neurotech: Utah-based implantable brain-computer interface company developing neural recording/stimulation platforms for paralysis and other indications. Directly comparable as a peer implantable BCI company; COO Nick Halper previously led growth strategy and regulatory work at Blackrock before joining Motif.
  • Neuralink: Elon Musk-founded implantable BCI company developing high-bandwidth cortical interfaces for paralysis and eventually other applications. Directly comparable as a peer implantable BCI; competes for the same press coverage, talent, and clinical site attention as Motif in the BCI race.
  • Synchron: Stentrobot-derived endovascular BCI company targeting paralysis patients via a less-invasive, catheter-delivered electrode. Directly comparable as a peer BCI for clinical applications and as a competitor for patient/clinical-site mindshare in the implantable neurotech category.
  • Precision Neuroscience: Neuralink co-founder-founded BCI company developing a thin-film cortical electrode array for high-resolution brain recording. Directly comparable as a peer implantable BCI startup competing for talent, capital, and clinical milestones in the cortical-interface space.
  • Paradromics: Austin-based implantable BCI company building high-data-rate neural recording interfaces for medical and communication applications. Directly comparable as a peer implantable BCI startup; competes in the same clinical-stage BCI cohort as Motif.

Broad incumbents

  • Medtronic: Global medical device leader with deep franchises in deep brain stimulation (Activa), spinal cord stimulation, and other neuromodulation therapies. Broad incumbent in the neuromodulation category; CTO Steve Goetz's 26-year Medtronic tenure and Bakken Fellowship make it the most directly relevant incumbent for talent/technology benchmarking, even though Medtronic's DBS targets movement disorders rather than TRD.
  • Abbott: Major neuromodulation player with FDA-approved dorsal root ganglion and spinal cord stimulation systems (Proclaim, Eterna) and a deep DBS legacy via the legacy St. Jude portfolio. Broad incumbent in implantable neuromodulation; directly comparable on Class III implant manufacturing, regulatory, and commercial scale.
  • Boston Scientific: Large-cap medical device incumbent with spinal cord stimulation, deep brain stimulation, and cardiac rhythm management franchises. Broad incumbent in implantable neuromodulation; Director of Manufacturing Jake Wiederin spent more than a decade at Boston Scientific supporting cardiac rhythm and neuromodulation portfolios.
  • Saluda Medical: Clinical-stage neuromodulation company developing closed-loop spinal cord stimulation for chronic pain with Evoke/ECAP-controlled devices. Comparable as a peer implantable neuromodulation company with a sensing-enabled platform; multiple Motif engineers and staff previously worked at Saluda, making it a near-direct talent/technology comparator.

Emerging players

  • BrainsWay: Commercial-stage company commercializing deep transcranial magnetic stimulation (Deep TMS) systems, including an FDA-cleared protocol for treatment-resistant depression. Comparable as a peer targeting TRD with a non-invasive neuromodulation modality that competes for the same patient population and clinical sites as Motif's eventual DOT offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Motif Neurotech social profiles

Digital presence

Motif Neurotech compliance and trust

Trust signal

Compliance4 records

Motif Neurotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Motif Neurotech leadership team

Management profile

Number of profiles

Profiles19 records

Motif Neurotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Motif Neurotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Motif Neurotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Motif Neurotech

What does Motif Neurotech do?

Motif Neurotech develops a minimally invasive, wirelessly powered implantable brain stimulator called DOT (Digitally programmable Over-brain Therapeutic), also referenced as the DOT XCS System. The pea-sized, battery-free device is implanted in the skull bone above the dura in a ~20–30 minute outpatient procedure and pairs with a wearable hat controller to deliver targeted stimulation of the Central Executive Network (CEN) for the treatment of treatment-resistant depression. The company is clinical-stage, having received FDA Investigational Device Exemption (IDE) approval in April 2026 for its RESONATE Early Feasibility Study.

Is Motif Neurotech a public or private company?

Motif Neurotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Motif Neurotech founded?

Motif Neurotech was founded in 2022. It employs 11 to 50 people.

Where is Motif Neurotech based?

Motif Neurotech is headquartered in Houston, United States, in the North America region.

How does Motif Neurotech make money?

Two revenue lines are on record. Pre-revenue (clinical-stage) is the primary driver. The others are non-dilutive Grant Funding.

Who are Motif Neurotech's main competitors?

Direct peers on record are Blackrock Neurotech, Neuralink, Synchron, Precision Neuroscience and Paradromics. Broad incumbents are Medtronic, Abbott, Boston Scientific and Saluda Medical. BrainsWay is listed as an emerging player.

Does Motif Neurotech have an API?

No public API is recorded for Motif Neurotech.

What industry is Motif Neurotech in?

Motif Neurotech's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Inc.This Brain Implant Could Treat Depression—It Just Got Cleared For Human TrialsMotif Neurotech, a Houston-based brain-computer interface company, announced last month that the US Food and Drug Administration approved their human study to test a brain implant that sends electrical signals to treat severe depression. The implant, about the size of a blueberry, sits in the skull and targets the central executive network (CEN), which is underactive in major depressive disorder, emitting specific stimulation patterns to activate the network. The company was founded with the mission to build neural devices that give people suffering from mental health conditions the opportunity for a better life.In VivoMotif Neurotech Begins Its Biggest Test Yet, And So Does Therapeutic BCIMotif Neurotech has begun an FDA-authorized trial for its DOT brain implant, a minimally invasive device designed to treat depression in patients who have not responded to medication. The implant is designed to fit existing surgical workflows at roughly 4,000 US outpatient facilities, but researchers face fundamental challenges in interpreting the brain's signals to enable adaptive, real-time stimulation. The technology represents a milestone for therapeutic brain-computer interfaces, though a fully closed-loop system that can read mood states and respond in real time remains a long-term goal.InnovationMapHouston startup’s brain implant for depression advances to clinical trialHouston-based Motif Neurotech has received FDA approval to begin its first clinical trial for the DOT stimulator, a minimally invasive brain implant designed to treat treatment-resistant depression. The company is collaborating with multiple medical institutions, including Baylor College of Medicine and Massachusetts General Brigham, while also participating in ARPA-H's EVIDENT initiative to gather additional efficacy data. This milestone follows the startup's recent Series A funding round and represents a significant step in developing continuous bioelectronic therapies for mental health disorders.Med-Tech InsightsMintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental HealthMintNeuro and Motif Neurotech announced a strategic partnership to combine MintNeuro's miniaturised neural interface chip technology with Motif's clinical-stage therapeutic BCI implant platform for mental health conditions. The collaboration includes a multi-year commercial supply agreement and builds on over a year of joint development, with Motif's sensing chip already integrated into devices used in pre-clinical work. Motif recently received FDA approval to begin a US clinical trial for its DOT device, a blueberry-sized implantable brain stimulator for treatment-resistant depression, and the partnership aligns with a 4.7 million GBP UK government ARIA-funded Brain Mesh project.TipranksMintNeuro Clinches Multi-Year Motif Neurotech Deal to Power Miniature Mental Health BCIsMintNeuro, an Imperial College London spinout specializing in semiconductor solutions for neural implants, has signed a multi-year supply agreement with Motif Neurotech to provide chips for miniature brain-computer interface (BCI) devices targeting mental health conditions including depression and treatment-resistant depression. The partnership builds on a year of joint architecture design and pre-clinical hardware validation, with Motif establishing a U.K. subsidiary to collaborate with MintNeuro on software and data science tied to the ARIA-funded Brain Mesh project. Motif has received U.S. FDA clearance to begin clinical trials for its DOT implant, a blueberry-sized device designed for outpatient placement, with MintNeuro's chips enabling neuromodulation, real-time monitoring, and closed-loop stimulation functions.Popular ScienceA brain implant to treat depression gets FDA greenlight to start trialsThe FDA has approved Motif Neurotech to begin human trials for its DOT brain implant, a blueberry-sized device designed to treat treatment-resistant depression through wireless electrical stimulation of specific brain regions. The 12-month trial will involve approximately 10 participants who have not responded to other treatments, with researchers assessing both safety and early signs of efficacy. If successful, the device would become the first brain-computer interface used specifically for clinical depression treatment, representing a modernized approach to neural stimulation therapy.ZME ScienceA Tiny Skull Implant That Treats Depression From Home Just Cleared Its First TrialMotif Neurotech, a Houston-based startup, has received FDA approval for an Investigational Device Exemption to begin an early feasibility study of its Motif DOT XCS System, a tiny brain-stimulation implant placed in the skull bone for people with treatment-resistant depression. The RESONATE trial will enroll patients whose depression has not improved after at least two antidepressant medications and track safety over 12 months across up to eight medical institutions including Baylor College of Medicine, Massachusetts General Brigham, and Emory Healthcare. If the approach proves safe and effective, it could offer a middle ground between noninvasive treatments like transcranial magnetic stimulation and more invasive deep brain stimulation implants.YahooMintNeuro and Motif Neurotech collaborate for mental health therapiesMintNeuro has signed a multi-year commercial supply agreement with Motif Neurotech to advance miniature brain-computer interface (BCI) therapy for mental health conditions such as depression and bipolar disorder. Under the agreement, Motif Neurotech will incorporate MintNeuro's miniaturized sensing and stimulation integrated circuits through pre-clinical, early clinical, and pivotal trial phases, while MintNeuro gains real-world system validation and feedback on chip requirements. Motif Neurotech recently received FDA approval to begin a clinical trial for treatment-resistant depression.BolsamaniaMintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental HealthMintNeuro and Motif Neurotech announced a strategic partnership to combine MintNeuro's neural sensing and stimulation integrated circuits with Motif's clinical-stage therapeutic BCI implant platform for mental health applications. The multi-year commercial supply agreement gives Motif access to miniaturised chip technology while providing MintNeuro with a direct pathway to clinical application and real-world device validation. Motif recently received FDA approval to begin US clinical trials for its DOT device, a blueberry-sized implantable neural device for treatment-resistant depression, and has raised over $30 million in venture capital funding.AijournMintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental HealthMintNeuro and Motif Neurotech have announced a strategic partnership combining MintNeuro's miniaturized neural sensing and stimulation integrated circuits with Motif's clinical-stage therapeutic brain-computer interface platform to accelerate implantable BCI devices for mental health conditions including treatment-resistant depression. The agreement includes a multi-year commercial supply arrangement and builds on over a year of prior collaboration, including the £4.7 million UK ARIA-funded Brain Mesh project, with Motif's FDA-approved DOT device already integrating MintNeuro's chips in pre-clinical work. The partnership aligns MintNeuro's chip development roadmap with Motif's clinical program toward closed-loop therapeutic neuromodulation, supporting Motif's broader goal of delivering ultra-miniature implants that can be placed in outpatient procedures.